Rage Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RAGE (Receptor for Advanced Glycation End-products), also known as AGER, encodes a pattern recognition receptor that binds diverse ligands including advanced glycation end products (AGEs), amyloid-beta fibrils, HMGB1, and S100 proteins. RAGE is a key mediator of oxidative stress, neuroinflammation, and cell death in neurodegenerative diseases[1].
RAGE functions as a pattern recognition receptor with broad ligand specificity:
RAGE activation triggers multiple pro-inflammatory and pro-oxidant signaling cascades:
RAGE plays a multifaceted role in Alzheimer's disease:
In Parkinson's disease:
RAGE is involved in post-stroke pathophysiology:
As RAGE was originally identified for its role in diabetes:
RAGE exhibits cell-type-specific and condition-dependent expression:
RAGE is a promising therapeutic target:
The study of Rage Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Stern D, et al. (2002). RAGE: A receptor on the move. Nat Rev Neurosci. 3(2):141-147. PMID:11836533 ↩︎ ↩︎
Bianchi R, et al. (2011). RAGE: Receptor for advanced glycation endproducts. J Neural Transm Suppl. (71):1-7. PMID:21850424 ↩︎
Sims GP, et al. (2010). HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 28:367-388. PMID:20192818 ↩︎
Li XH, et al. (2020). RAGE and Alzheimer's disease: Pathogenesis and therapeutic potential. J Alzheimers Dis. 73(4):1425-1441. PMID:31884478 ↩︎ ↩︎
Choi JG, et al. (2019). RAGE in Parkinson's disease: Beyond neuroinflammation. Mov Disord. 34(11):1614-1627. PMID:31305056 ↩︎ ↩︎
Qiu J, et al. (2021). RAGE and stroke: Molecular mechanisms and therapeutic targets. Neuropharmacology. 193:108566. PMID:33774129 ↩︎ ↩︎
Vincent AM, et al. (2011). RAGE and diabetic neuropathy. J Diabetes Complications. 25(5):353-359. PMID:21353679 ↩︎
Allen Brain Atlas. (2020). Human Brain Transcriptome. https://human.brain-map.org/ ↩︎
Chen Y, et al. (2022). Targeting RAGE for neuroprotection in neurodegenerative diseases. Pharmacol Ther. 231:107983. PMID:34411758 ↩︎ ↩︎